Caroline Phillips

• Summarising RXC007 in vivo antifibrotic activity across preclinical rodent fibrosis models
• Presentation of RXC007 Ph2a anti-fibrotic signals in Ph2a IPF trial
• Exploratory circulating biomarkers in IPF and presentation of RXC007 changes

This panel brings together experts from across various disease indications to explore the evolving scientific, translational, and clinical landscape of antifibrotic drug development to provide forward-looking perspective on where antifibrotic science is heading, which challenges are most urgent to overcome, and how industry and academia can collaborate more effectively to accelerate progress across diverse indication.

Discussion Topics Include:

• Emerging Key scientific breakthroughs and novel therapeutic targets shaping the future of antifibrotic drug development across multiple organ systems.
• Identify the key translational and clinical challenges hindering progress, including biomarker validation, patient stratification, and trial design optimization
• How emerging antifibrotic therapies can be integrated into existing treatment paradigms and the potential for combination strategies to improve patient outcomes